132 citations
,
September 2021 in “Frontiers in Public Health” The study highlighted that COVID-19 was not solely a respiratory disease but a multisystem disease with both pulmonary and extrapulmonary manifestations. It emphasized that while some patients were asymptomatic, symptomatic cases could present with mild to severe pulmonary symptoms or extrapulmonary symptoms such as gastroenteritis, fever, or vomiting. Severe cases could lead to complications like acute kidney injury, heart failure, and venous thromboembolic events due to high viral load or cytokine storm. The study underscored the importance of recognizing these manifestations for early diagnosis and controlling the spread of the infection.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
18 citations
,
June 2021 in “Endocrinology”
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
89 citations
,
August 2013 in “PloS one” Androgen receptors are active in many tissues of both male and female mice, not just reproductive organs.
14 citations
,
April 2006 in “Expert Review of Dermatology” Antiandrogen therapy helps treat genetic hair loss.